Patents

Apolin Bio and Viva Biotech present new ApoA/APOB interaction inhibitors

Thu, 09 Jul 2026 09:00:00 -0400

Apolin Bio Ltd. and Shanghai Viva Dancheng Entrepreneurship Incubator Management Ltd. have detailed polycyclic compounds acting as apolipoprotein A (ApoA; LPA)/apolipoprotein B-100 (APOB) interaction inhibitors that are potentially useful for the treatment of cardiovascular disorders.

Nuvalent discloses new AKT1 inhibitors

Thu, 09 Jul 2026 09:00:00 -0400

Nuvalent Inc. has described RAC-α serine/threonine-protein kinase (AKT1; PKBα) E17K mutant inhibitors reported to be useful for the treatment of cancer.

U&S Bio identifies new H+/K+-ATPase inhibitors

Thu, 09 Jul 2026 09:00:00 -0400

U&S Bio Co. Ltd. has divulged H+/K+-ATPase inhibitors with improved stability found to be potentially useful for the treatment of gastrointestinal disorders, cancer, Helicobacter pylori infection, sialorrhea, asthma and airways obstruction, among others.

Prelude Therapeutics patents new KAT6A-targeting PROTACs

Thu, 09 Jul 2026 09:00:00 -0400

Prelude Therapeutics Inc. has synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin-protein ligase (CRBN)-binding moiety coupled to a histone acetyltransferase KAT6A (MOZ; MYST-3)-targeting moiety that are potentially useful for the treatment of cancer.

Promomed Rus discovers new JAK inhibitors

Thu, 09 Jul 2026 09:00:00 -0400

Promomed Rus LLC has identified Janus kinase (JAK) inhibitors reported to be useful for the treatment of alopecia, atopic dermatitis, juvenile arthritis, rheumatoid arthritis, systemic lupus erythematosus and psoriatic arthritis.

Beijing Mabworks Biotech discloses new DLL3-targeting ADCs

Wed, 08 Jul 2026 09:00:00 -0400

A Beijing Mabworks Biotech Co. Ltd. patent describes new antibody-drug conjugates (ADCs) comprising antigen-binding fragments or antibodies targeting delta-like protein 3 (DLL3) linked to a cytotoxic drug potentially useful for the treatment of small-cell lung cancer (SCLC).

Beijing Jingwei-Yankang Biomedical divulges new RBP4 inhibitors

Wed, 08 Jul 2026 09:00:00 -0400

Beijing Jingwei-Yankang Biomedical Co. Ltd. has reported new phenyl-substituted heterocyclic compounds acting as retinol-binding protein 4 (RBP4) inhibitors with potential in the treatment of age-related macular degeneration (AMD).

KU Leuven and Universität Zürich describe new PTPN1/PTPN2 inhibitors

Wed, 08 Jul 2026 09:00:00 -0400

KU Leuven and Universität Zürich have discovered new tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors potentially useful for the treatment of cancer and metabolic diseases.

Pikavation Therapeutics identifies new PI3Kα inhibitors

Wed, 08 Jul 2026 09:00:00 -0400

Pikavation Therapeutics Inc. has patented new phosphatidylinositol 3-kinase α (PI3Kα) inhibitors potentially useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA-related overgrowth spectrum.

Nurix Therapeutics patents new SMARCA2-targeting PROTACs

Wed, 08 Jul 2026 09:00:00 -0400

Nurix Therapeutics Inc. has disclosed new proteolysis targeting chimera (PROTAC) compounds potentially useful for the treatment of cancer.

Wigen Biomedicine Technology identifies new PI3Kα modulators